Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma
Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if the combination of 3 drugs
(gemcitabine, capecitabine, and bevacizumab) can help to control metastatic or unresectable
renal cell carcinoma. The safety of this drug combination will also be tested.